Saturday's attack is the biggest on Saudi oil infrastructure since Saddam Hussein's invasion of Kuwait in 1990.Energyread more
Saudi Aramco is aiming to restore by Monday about a third of its crude output that was disrupted after drone attacks on two key oil facilities, The Wall Street Journal...Marketsread more
"Blaming Iran won't end disaster. Accepting our April '15 proposal to end war & begin talks may," Zarif said on Twitter.Energyread more
Oil prices are expected to jump as much as $10 per barrel after a coordinated drone strike hit Saudi Arabia's largest oil field, forcing the kingdom to cut its oil output in...Marketsread more
Apple's new iPhones can still send texts, download apps, and make video calls, but the company spends a lot of time and effort marketing its new phones as powerful photography...Technologyread more
The trucking industry is worth hundreds of billions of dollars per year. Uber is going after this market with Uber Freight, an online platform that matches truckers with...Technologyread more
Some U.S. manufacturers say tariffs, if targeted, will help address longstanding unfair trade practices like intellectual property theft.Traderead more
Supporters of a $15 minimum wage ballot initiative in Florida argue the state's inflation-tied pay hikes have not gone far enough.2020 Electionsread more
Saudi Arabia shut down half its oil production Saturday after drone strikes hit the world's largest oil processing facility in an attack claimed by Yemen's Houthi rebels.Politicsread more
Trusii's hydrogen water machines were supposed to help users with their health problems, but customers claim the company is involved in a giant scam.Technologyread more
The decoupling of the world's two weightiest economies seems as inescapable as its extent and global impact remains incalculable.Politicsread more
cancer@ (Adds detail, quote)
ZURICH, Aug 29 (Reuters) - Roche's Tecentriq has won European approval for use against a tough-to-treat breast cancer, helping the Swiss drugmaker to widen use of an immunotherapy that has so far been eclipsed in revenue terms by more-established rival medicines.
The European Commission approved Tecentriq with Abraxane for people with metastatic triple-negative breast cancer that tests positive for a protein believed to help tumours to evade attack by the body's immune system, Roche said on Thursday.
Tecentriq trailed rival immunotherapies Keytruda and Opdivo - produced by Merck and Bristol-Myers Squibb respectively - to market but has been racking up approvals.
These include approvals for niche indications such as metastatic triple-negative breast cancer. Some 15-20% of breast cancer is triple-negative, meaning tumours lack three characteristics for which there are more treatment options.
"The European approval of this Tecentriq combination represents a significant step forward in the treatment of this aggressive breast cancer, where the unmet medical need is great," Roche Chief Medical Officer Sandra Horning said in a statement.
Tecentriq, having steadily added approvals in new cancer indications and new geographies, is on track to surpass $1.5 billion in annual sales in 2019, its third full year on the market.
Opdivo and Keytruda, which had a two-year head start on Tecentriq, achieved sales of $6.7 billion and $7.2 billion respectively in 2018.
(Reporting by John Miller Editing by David Goodman)